Aquatic Capital Management Trims Stake in Regeneron Pharmaceuticals

Institutional investor reduces position in biopharmaceutical company

Mar. 16, 2026 at 7:23am

Got story updates? Submit your updates here. ›

Aquatic Capital Management LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 73.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,831 shares of the biopharmaceutical company's stock after selling 38,194 shares during the period.

Why it matters

Regeneron Pharmaceuticals is a major player in the biopharmaceutical industry, known for its innovative drug discovery technologies. Institutional investors' trading activity in the company's stock can provide insights into market sentiment and potential shifts in the broader industry.

The details

Aquatic Capital Management sold a significant portion of its Regeneron Pharmaceuticals holdings in the 3rd quarter, reducing its stake by 73.4%. The firm now owns 13,831 shares of the biopharmaceutical company's stock, down from 52,025 shares previously. This move suggests Aquatic Capital Management may have shifted its investment strategy or portfolio allocation for Regeneron.

  • Aquatic Capital Management filed its 13F report for the 3rd quarter of 2026.

The players

Aquatic Capital Management LLC

An institutional investor that manages a portfolio of investments, including shares in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the dynamic nature of institutional investment strategies and the ongoing shifts in the biopharmaceutical industry. Investors and analysts will likely monitor Regeneron's stock performance and any further changes in major shareholders' positions.